NCT00612417

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

A Randomised, Double-blind and Placebo-controlled Study Investigating the Pharmacodynamic Effects of Administration of Recombinant Human Factor VIII in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: ThromboGenics · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Single administration of recombinant FVIII/placebo in healthy male subjects who have been treated with a single dose of anti-factor VIII antibody, TB-402

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402	Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-03-01
• Completion: 2008-06-01
• First posted: 2008-02-11
• Last updated: 2014-04-07

Locations

1 site across 1 country: Denmark